selexipag is a selective prostacyclin receptor agonist with vasodilatory and anti-proliferative effects. It acts on the prostacyclin receptor (IP receptor) to increase the production of cyclic adenosine monophosphate (cAMP) in vascular smooth muscle cells.
This leads to vasodilation, inhibition of platelet aggregation, and suppression of smooth muscle cell proliferation. selexipag is primarily used for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and delay disease progression. It has a broad spectrum of action, targeting multiple components involved in PAH pathophysiology.